- Home
- IDYA vs SRCE Comparison
IDYA vs SRCE Comparison
Compare IDYA & SRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SRCE
- Stock Information
- Founded
- IDYA 2015
- SRCE 1863
- Country
- IDYA United States
- SRCE United States
- Employees
- IDYA N/A
- SRCE N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SRCE Major Banks
- Sector
- IDYA Health Care
- SRCE Finance
- Exchange
- IDYA Nasdaq
- SRCE Nasdaq
- Market Cap
- IDYA 1.9B
- SRCE 1.5B
- IPO Year
- IDYA 2019
- SRCE N/A
- Fundamental
- Price
- IDYA $24.27
- SRCE $61.15
- Analyst Decision
- IDYA Strong Buy
- SRCE Buy
- Analyst Count
- IDYA 13
- SRCE 2
- Target Price
- IDYA $50.82
- SRCE $72.00
- AVG Volume (30 Days)
- IDYA 1.0M
- SRCE 79.6K
- Earning Date
- IDYA 08-05-2025
- SRCE 07-24-2025
- Dividend Yield
- IDYA N/A
- SRCE 2.45%
- EPS Growth
- IDYA N/A
- SRCE 14.42
- EPS
- IDYA N/A
- SRCE 5.69
- Revenue
- IDYA $7,000,000.00
- SRCE $388,840,000.00
- Revenue This Year
- IDYA $115.83
- SRCE $14.53
- Revenue Next Year
- IDYA $252.50
- SRCE $2.46
- P/E Ratio
- IDYA N/A
- SRCE $10.92
- Revenue Growth
- IDYA N/A
- SRCE 7.96
- 52 Week Low
- IDYA $13.45
- SRCE $52.14
- 52 Week High
- IDYA $44.42
- SRCE $68.13
- Technical
- Relative Strength Index (RSI)
- IDYA 63.79
- SRCE 40.56
- Support Level
- IDYA $21.33
- SRCE $63.38
- Resistance Level
- IDYA $25.54
- SRCE $64.60
- Average True Range (ATR)
- IDYA 1.00
- SRCE 1.11
- MACD
- IDYA 0.20
- SRCE -0.41
- Stochastic Oscillator
- IDYA 70.60
- SRCE 12.11
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.